Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
SPTX · Why this verdict
Why Seaport Therapeutics (SPTX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.7/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Seaport Therapeutics is a speculative, pre-revenue biotech with institutional accumulation and a $32.19 analyst target 56.2% above the $20.61 price, but quality is 2.5/10 and its last two reports missed estimates by wide margins.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The $32.19 analyst target sits 56.2% above the $20.61 price, a reward-to-risk of 3.75 against a 15.0% downside to the stop. Estimated upside | The price rerates toward the analyst target as clinical and corporate milestones are met. | →Stable |
| CounterCoverage is light (8 analysts) and biotech targets depend on binary trial outcomes, so the target can be cut sharply on one failure. | ||
Losses are larger than expected: the last two reports missed by 171% and 166%, with EPS of -$1.78 against a -$0.66 estimate and no revenue reported. Earnings | Losses per share come in at or better than estimates in the report due 2026-11-12. | ↑Improving |
| CounterBiotech loss estimates are volatile and driven by trial spending timing, so large percentage misses may carry little signal. | ||
The stock carries binary industry risk, which places it in the speculative category with all gains and losses tied to clinical outcomes. Suitability rationale | Clinical programs advance without a setback, with price holding above the $19.17 stop. | →Stable |
| CounterA single failed trial can erase most of the market value, and downside is 15.0% to the stop on routine moves alone. | ||
Institutions are accumulating shares, with the holder-change component at 10/10 and no net insider activity. Insider breakdown | Institutional ownership keeps rising over the next 12 months. | →Stable |
| CounterInstitutional buying near a recent IPO-era price can reverse quickly if lock-up expiries or financing needs push selling. | ||
Momentum is solid at 6.2/10, with a MACD component of 10/10 and rising on-balance volume pointing to accumulation. Momentum breakdown | Momentum holds above 5/10 over the next few quarters. | ↓Deteriorating |
| CounterBollinger and support/resistance scores are very low (0.8 and 2.2), so the price may already be at the top of its range. | ||
The $32.19 analyst target sits 56.2% above the $20.61 price, a reward-to-risk of 3.75 against a 15.0% downside to the stop.
→StableEstimated upside
- Expectation
- The price rerates toward the analyst target as clinical and corporate milestones are met.
CounterCoverage is light (8 analysts) and biotech targets depend on binary trial outcomes, so the target can be cut sharply on one failure.
Losses are larger than expected: the last two reports missed by 171% and 166%, with EPS of -$1.78 against a -$0.66 estimate and no revenue reported.
↑ImprovingEarnings
- Expectation
- Losses per share come in at or better than estimates in the report due 2026-11-12.
CounterBiotech loss estimates are volatile and driven by trial spending timing, so large percentage misses may carry little signal.
The stock carries binary industry risk, which places it in the speculative category with all gains and losses tied to clinical outcomes.
→StableSuitability rationale
- Expectation
- Clinical programs advance without a setback, with price holding above the $19.17 stop.
CounterA single failed trial can erase most of the market value, and downside is 15.0% to the stop on routine moves alone.
Institutions are accumulating shares, with the holder-change component at 10/10 and no net insider activity.
→StableInsider breakdown
- Expectation
- Institutional ownership keeps rising over the next 12 months.
CounterInstitutional buying near a recent IPO-era price can reverse quickly if lock-up expiries or financing needs push selling.
Momentum is solid at 6.2/10, with a MACD component of 10/10 and rising on-balance volume pointing to accumulation.
↓DeterioratingMomentum breakdown
- Expectation
- Momentum holds above 5/10 over the next few quarters.
CounterBollinger and support/resistance scores are very low (0.8 and 2.2), so the price may already be at the top of its range.
Per-dimension breakdown
Quality
2.5/10data confidence 86%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 5.5 |
| Piotroski F | 4.4 |
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.6 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 5.5 |
| Volume | 8.7 |
- ▸Volume distribution (falling OBV)
Sentiment
7.9/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.9 |
| Price target | 9.9 |
| erm sentiment | 5.5 |
- ▸Light analyst coverage (8.0) — signal dampened
- ▸Analyst upside: 82%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.6/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
3.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.1 |
| support resistance | 2.7 |
| 52w position | 4.4 |
| gap | 6.0 |
Risk (lower is worse)
4.1/10data confidence 80%| Component | Sub-score |
|---|---|
| short interest | 6.3 |
| days to cover | 0.0 |
| volatility | 0.0 |
| debt equity | 10.0 |
Catalyst
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 5.0 |
- ▸Earnings concerns: 0B/2M
- ▸Earnings in 13 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (7)
- MOMENTUM:5.8>=5.5
- ASYMMETRY:3.9>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- EARNINGS_PROXIMITY:13d<=14d (soft)
Reward-to-Risk
3.86
Upside
+57.9%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($1.1B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Value at 9.0 and asymmetric R:R of 3.86.
The strongest dimensions are Value at 9.0, Sentiment at 7.9, and Insider at 7.3; the weakest are Quality at 2.5, Catalyst at 3.0, and Technical at 3.8. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 3.86 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Large Analyst Target Gap
Trip ifThe analyst target falls below $25 from the current $32.19.
- P2Widening Losses Vs Estimates
Trip ifEPS surprise exceeds 0% for 2 consecutive quarters.
- P3Binary Biotech Risk
Trip ifPrice falls below the $19.17 stop level from the current $20.61.
- P4Institutional Accumulation
Trip ifThe holder-change component falls below 5.0 from the current 10.0.
- P5Rising Volume Momentum
Trip ifThe momentum score falls below 4.5 from the current 6.2.